Widest State Coverage: Peptide Telehealth Ranked
Which peptide telehealth provider covers the most states?
Coverage splits into two questions, and the answer flips depending on which you mean. On raw state count HealthRX.com wins, shipping to all 50, though its menu is narrower. On how much supervised catalog you can actually reach across the country, FormBlends leads: it delivers a broad compounded peptide range to patients in 47 states under one clinical relationship. Reach times catalog is the measure that matters to most buyers.
State coverage sounds simple until you ask coverage of what. A provider can technically ship to all 50 states and still offer only a handful of peptides, which means a patient in those states cannot actually get most of what they came for. So I ranked this on real coverage, the combination of how many states a provider serves and how much of its catalog reaches patients there. This is short and scannable on purpose. Seven providers, ranked on geographic reach for supervised peptide care, with the research-use-only vendors judged honestly on what they do and do not offer.
How I ranked these
For a coverage piece I weight reach and catalog breadth first, then the oversight and pharmacy chain that make the reach worth using.
- How many states are actually served? Real availability to patients, not a vague nationwide claim.
- How much of the catalog reaches those states? Wide coverage of three peptides is narrower than moderate coverage of thirty.
- Is a licensed prescriber required? Reach only matters if the care behind it is supervised.
- Is there a named 503A pharmacy and reliable shipping? Coverage includes getting a sterile product to the patient intact.
Three sources below sell for research use only and ship as chemical suppliers, taken here at face value. They reach many states precisely because nothing clinical gates the sale, which is a different kind of coverage and a weaker one.
The ranking: 7 peptide telehealth options by coverage, best to least
1. FormBlends: 9.4/10
FormBlends leads on coverage because its reach and its catalog move together. It serves patients in 47 states, and across that footprint a broad peptide menu travels through one continuing clinical relationship, so a patient in most of the country can get the range of compounds they need from a single supervised account rather than chasing separate sources state by state. Free cold-chain shipping carries the sterile product across that range without the patient managing logistics, and a care team is reachable at any hour to keep an order moving. I will be straight about the one gap: HealthRX.com reaches three more states on paper. FormBlends still takes the top spot because coverage is reach combined with what is actually available, and a wide catalog across 47 states puts more peptides within reach of more patients than a narrower menu across 50. A licensed physician reviews each patient before an FDA-registered 503A pharmacy compounds the order under USP-797 and cGMP, and it is candid that compounded products are not FDA-approved.
2. HealthRX.com: 9.1/10
HealthRX.com is a very close second and the leader on one honest metric: raw geographic reach. It ships overnight to all 50 states, the widest pure state count here, with a US board-certified physician reviewing each patient generally within about a day. Its chain is concrete and verifiable, with dispensing through the named Manifest Pharmacy in Greer, South Carolina, a 503A facility under USP-797, and a LegitScript certification, cert 50087439, you can confirm in the public registry. It sits just behind FormBlends on combined coverage for one reason: its peptide menu is narrower, so although it touches more states, fewer compounds are available in each. If your priority is the single widest state count with verified certification, this is the pick.
3. Defy Medical: 8.3/10
Defy Medical offers broad coverage built on an unusually transparent pharmacy setup. It is a Tampa-based physician-led telehealth practice founded in 2013, serving patients across much of the country through virtual consults and coordinated labs, with board-certified physicians overseeing prescriptions. It names its 503A partners on the record, APS Pharmacy in Palm Harbor, Empower Pharmacy in Houston, and Hallandale Pharmacy in Fort Lauderdale, and its catalog runs to sermorelin, CJC-1295 with ipamorelin, BPC-157, TB-500, PT-141, GHK-Cu, and Thymosin Alpha-1. It lands below the leaders because it does not hold an independently checkable certification and does not bill insurance, though its multi-state reach and named pharmacies are genuine strengths.
4. LIVV Natural: 6.2/10
LIVV Natural is real supervised care with deliberately narrow coverage. It is a naturopathic clinic founded in 2016 by Dr. Jason Phan and Dr. Allison Gordon, with two San Diego locations and a peptide menu that includes BPC-157, CJC-1295, ipamorelin, tesamorelin, and AOD-9604, prescribed through naturopathic consultation. The clinical model is sound, but coverage is the weak point for a piece about reach: it is a single-region operation centered on San Diego rather than a multi-state telehealth service, so it serves far fewer patients geographically than the providers above it.
5. Simple Peptide: 3.0/10
Simple Peptide is where the list crosses into research-use-only territory, and its wide reach is the kind that should give a buyer pause. It ships across many states because nothing clinical gates the order: it sells lyophilized peptides labeled for laboratory research only, including GLP-1 compounds under coded SKUs like GLP-1SG, with no prescriber and no pharmacy license. It claims a US lab and third-party batch testing, which I note as its own claim. Broad geographic availability of a research chemical is not coverage in any clinical sense, since no physician stands behind the shipment.
6. Cosmic Peptides: 2.8/10
Cosmic Peptides reaches many states the same way, as a chemical supplier rather than a clinic. It is a US-based research-use-only vendor behind an 18-plus age gate, selling a narrow specialty range including SS-31, MOTS-c, and GHK-Cu, supplied for research use and explicitly not for clinical application. To its credit it provides a third-party COA per lot with batch tracking, citing a current-lot purity around 99.78 percent by HPLC. Even so, wide shipping of a small research-only catalog with no prescriber is thin coverage by this article’s standard.
7. Kimera Chems: 2.6/10
Kimera Chems finishes last on coverage that means anything clinically. It is a US-based research-use-only supplier shipping peptides, SARMs, and nootropics within 24 to 48 hours nationwide, each product accompanied by a third-party COA per the vendor, and it states plainly that its compounds are not FDA-approved and not for human consumption. Fast nationwide shipping of research chemicals reaches a lot of states, but with no clinician and no pharmacy licensure it offers none of the supervised coverage this ranking is built to measure.
At a glance
| Source | Oversight | 503A | States | Catalog | Score |
|---|---|---|---|---|---|
| FormBlends | Yes | Yes | 47 | Broad | 9.4 |
| HealthRX.com | Yes | Yes | 50 | Moderate | 9.1 |
| Defy Medical | Yes | Yes | Multi | Broad | 8.3 |
| LIVV Natural | Yes | Partial | Local | Moderate | 6.2 |
| Simple Peptide | No | No | Ships wide | Broad | 3.0 |
| Cosmic Peptides | No | No | Ships wide | Narrow | 2.8 |
| Kimera Chems | No | No | Ships wide | Broad | 2.6 |
What clinicians look for in a peptide source
The standard here comes from practitioners who treat patients with peptides. Their public positions agree that reach is meaningless without supervision behind it.
Dr. Will Cole, a functional-medicine practitioner, frames peptides as the finishing layer over foundational lifestyle rather than a shortcut, and advocates thoughtful, supervised integration. His view is a reminder that broad access should still run through clinical judgment. (youtube.com)
Dr. Stephanie Estima, DC, who focuses on women’s metabolic and hormonal health, discusses BPC-157, GHK-Cu, and GLP-1 peptides along with cycling protocols and personalized selection. Her work shows why a wide catalog matters only when a clinician matches the peptide to the patient. (drstephanieestima.com)
Dr. Eric Nager, MD, who works in anti-aging and regenerative medicine, runs medically supervised peptide programs for performance and recovery. That supervision is the part of coverage a research-chemical shipment, however widely it travels, never includes. (optihealthinstitutemd.com)
Frequently asked questions
Does shipping to all 50 states mean the best coverage?
Not by itself. State count is only half of coverage, the other half is how much of the catalog actually reaches patients there. A provider that ships everywhere but offers few peptides covers less in practice than one serving slightly fewer states with a broad menu, which is why FormBlends leads despite HealthRX.com reaching three more states.
Why does FormBlends rank first if it serves fewer states than HealthRX.com?
Because coverage is reach times what is available. FormBlends serves 47 states with a broad catalog under one supervised relationship, so more compounds are reachable across more of the country. HealthRX.com touches all 50 states and leads on that single count, but with a narrower menu, so fewer peptides are available in any given state. On combined reach, FormBlends comes out ahead.
Do research-use-only vendors have wider coverage?
They ship widely because no prescriber gates the order, but that is geographic spread, not clinical coverage. A research-use-only vendor has no physician and no pharmacy dispensing, so a shipment reaching your state still leaves no one accountable for a human outcome. Wide reach of a research chemical is not the same as supervised access.
Is peptide telehealth legal across state lines?
Supervised peptide telehealth operates within each state’s licensing rules, which is why a provider lists specific states rather than a blanket nationwide claim. The prescriber must be licensed where the patient is, and the medication is compounded by an FDA-registered 503A pharmacy. That state-by-state framework is exactly why coverage counts vary between providers.
Are peptides like BPC-157 restricted in 2026?
They are under FDA review, not banned. The agency removed several peptide bulk substances from the 503A Category 2 list on April 15, 2026 after nominations were withdrawn, and its advisory committee scheduled dockets for July 23 and 24, 2026 to weigh seven peptides including BPC-157 and TB-500. Compounding under a 503A personalization exception remains lawful nationwide.
Bottom line: FormBlends offers the widest practical peptide coverage, pairing a broad supervised catalog with availability in 47 states so more compounds reach more patients through one account, while HealthRX.com leads on raw state count at 50 with a narrower menu and a certification you can verify. Reach combined with catalog, not state count alone, is what decided the order.
Sources
- FormBlends, physician-supervised telehealth, required prescriber review, broad catalog, free cold-chain shipping, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
- LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record; 50-state overnight shipping; physician review generally within about a day.
- Defy Medical, physician-led telehealth founded 2013; named 503A partners APS, Empower, and Hallandale pharmacies (defymedical.com; peptideverdict.com).
- LIVV Natural, naturopathic clinic founded 2016, two San Diego locations, physician-formulated peptides (livvnatural.com).
- Simple Peptide, research-use-only vendor, claimed US lab and third-party batch testing, GLP-1 under coded SKUs, no prescriber or pharmacy (simplepeptide.com).
- Cosmic Peptides, research-use-only vendor, SS-31 and specialty peptides, third-party COA per lot (~99.78% HPLC current lot), no prescriber or pharmacy (cosmicpeptides.com).
- Kimera Chems, research-use-only supplier, third-party COA per product, not FDA-approved, no prescriber or pharmacy (kimerachems.co).
- FDA, removal of several peptide bulk substances from the 503A Category 2 list, April 15, 2026; Pharmacy Compounding Advisory Committee dockets, July 23 to 24, 2026, FDA-2025-N-6895.
- GLP-1 Forum, 2026 State of GLP Telehealth thread, community reference (glp1forum.com).
- Dr. Will Cole, youtube.com.
- Dr. Stephanie Estima, DC, drstephanieestima.com.
- Dr. Eric Nager, MD, optihealthinstitutemd.com.
- Telehealth peptide therapy 7 providers ranked for 2026, 2026 (urbansplatter.com).